Marone et al., 2020 - Google Patents
HIV gp120 induces the release of proinflammatory, angiogenic, and lymphangiogenic factors from human lung mast cellsMarone et al., 2020
View HTML- Document ID
- 7703053666641427693
- Author
- Marone G
- Rossi F
- Pecoraro A
- Pucino V
- Criscuolo G
- de Paulis A
- Spadaro G
- Marone G
- Varricchi G
- Publication year
- Publication venue
- Vaccines
External Links
Snippet
Human lung mast cells (HLMCs) express the high-affinity receptor FcεRI for IgE and are involved in chronic pulmonary diseases occurring at high frequency among HIV-infected individuals. Immunoglobulin superantigens bind to the variable regions of either the heavy …
- 101710023234 Segment 5 0 title abstract description 110
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Marone et al. | HIV gp120 induces the release of proinflammatory, angiogenic, and lymphangiogenic factors from human lung mast cells | |
| Varricchi et al. | Superantigenic activation of human cardiac mast cells | |
| Zhou et al. | Resistance of SARS-CoV-2 Omicron BA. 1 and BA. 2 variants to vaccine-elicited sera and therapeutic monoclonal antibodies | |
| Anand et al. | Interaction of human ACE2 to membrane-bound SARS-CoV-1 and SARS-CoV-2 S glycoproteins | |
| Demers-Mathieu et al. | Human milk antibodies against S1 and S2 subunits from SARS-CoV-2, HCoV-OC43, and HCoV-229E in mothers with a confirmed COVID-19 PCR, viral symptoms, and unexposed mothers | |
| Eisfeld et al. | Viral glycoproteins induce NLRP3 inflammasome activation and pyroptosis in macrophages | |
| Prescott et al. | Long-term single-dose efficacy of a vesicular stomatitis virus-based Andes virus vaccine in Syrian hamsters | |
| Jantarabenjakul et al. | Dynamics of neutralizing antibody and T-cell responses to SARS-CoV-2 and variants of concern after primary immunization with CoronaVac and booster with BNT162b2 or ChAdOx1 in health care workers | |
| Trinité et al. | Previous SARS-CoV-2 infection increases B. 1.1. 7 cross-neutralization by vaccinated individuals | |
| Flehmig et al. | Persisting neutralizing activity to SARS-CoV-2 over months in sera of COVID-19 patients | |
| Crosby et al. | Transgene expression and host cell responses to replication-defective, single-cycle, and replication-competent adenovirus vectors | |
| Ouyang et al. | Variable induction of pro-inflammatory cytokines by commercial SARS CoV-2 spike protein reagents: potential impacts of LPS on in vitro modeling and pathogenic mechanisms in vivo | |
| Beaudoin-Bussières et al. | SARS-CoV-2 accessory protein ORF8 decreases antibody-dependent cellular cytotoxicity | |
| Chimal-Eguia | Mathematical model of antiviral immune response against the COVID-19 virus | |
| Kant et al. | Quantifying anti-HIV envelope-specific antibodies in plasma from HIV infected individuals | |
| McEwan | Surveillance for intracellular antibody by cytosolic Fc receptor TRIM21 | |
| Beaudoin-Bussières et al. | A recent SARS-CoV-2 infection enhances antibody-dependent cellular cytotoxicity against Several Omicron subvariants following a fourth mRNA vaccine dose | |
| Cortes-Sarabia et al. | Variation in the humoral immune response induced by the administration of the BNT162b2 Pfizer/BioNTech vaccine: a systematic review | |
| Dabbagh et al. | Identification of the SHREK family of proteins as broad-spectrum host antiviral factors | |
| Ogrič et al. | Longitudinal analysis of antiphospholipid antibody dynamics after infection with SARS-CoV-2 or vaccination with BNT162b2 | |
| Marchitto et al. | Humoral responses elicited by SARS-CoV-2 mRNA vaccine in people living with HIV | |
| Chi et al. | Characteristics and roles of T follicular helper cells in SARS-coV-2 vaccine response | |
| Wang et al. | Synergistic effect by combining a gp120-binding protein and a gp41-binding antibody to inactivate HIV-1 virions and inhibit HIV-1 infection | |
| Boldova et al. | Theoretical explanation for the rarity of antibody-dependent enhancement of infection (ADE) in COVID-19 | |
| Langlois et al. | Infection of the Ex Vivo tonsil model by HTLV-1 Envelope-pseudotyped viruses |